Review
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Nov 28, 2017; 9(33): 1239-1252
Published online Nov 28, 2017. doi: 10.4254/wjh.v9.i33.1239
Global elimination of hepatitis C virus infection: Progresses and the remaining challenges
Reza Taherkhani, Fatemeh Farshadpour
Reza Taherkhani, Fatemeh Farshadpour, the Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr 7514633341, Iran
Author contributions: Farshadpour F designed the study and wrote the manuscript; Taherkhani R provided the literature review and edited the manuscript and was also involved in designing the study.
Conflict-of-interest statement: The authors declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Fatemeh Farshadpour, PhD, the Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Moallem Street, Bushehr 7514633341, Iran. f.farshadpour@bpums.ac.ir
Telephone: +98-917-1712653
Received: July 15, 2017
Peer-review started: July 19, 2017
First decision: August 15, 2017
Revised: September 1, 2017
Accepted: September 16, 2017
Article in press: September 16, 2017
Published online: November 28, 2017
Core Tip

Core tip: Despite the outstanding progresses in the management of hepatitis C virus (HCV) infection, the elimination of HCV would be difficult due to the emergence of injection drug use as the main source of HCV transmission. Asymptomatic nature of HCV infection, restricted accessibility to diagnostic approaches and appropriate antiviral treatments in the injecting drug users (IDUs) community are the root cause of failure in control of HCV infection among IDUs. These circumstances create a strong demand for timely diagnosis and proper treatment of HCV-infected patients as well as raising general awareness of HCV infection through public education to mitigate the risk of HCV transmission.